Lead Plaintiff Deadline: June 11, 2019
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(i) Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of purchased or acquired during the class period listed above.
If you suffered a loss in during the relevant time frame, you have until June 11, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.